Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of $300.89 billion. The enterprise value is $342.10 billion.
Important Dates
The last earnings date was Tuesday, February 3, 2026, before market open.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | Mar 16, 2026 |
Share Statistics
Merck & Co. has 2.47 billion shares outstanding. The number of shares has decreased by -1.34% in one year.
| Current Share Class | 2.47B |
| Shares Outstanding | 2.47B |
| Shares Change (YoY) | -1.34% |
| Shares Change (QoQ) | -0.40% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 79.98% |
| Float | 2.47B |
Valuation Ratios
The trailing PE ratio is 16.72 and the forward PE ratio is 23.78. Merck & Co.'s PEG ratio is 2.98.
| PE Ratio | 16.72 |
| Forward PE | 23.78 |
| PS Ratio | 4.71 |
| Forward PS | 4.51 |
| PB Ratio | 5.82 |
| P/TBV Ratio | 70.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 18.58 |
| PEG Ratio | 2.98 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 18.74 |
| EV / Sales | 5.26 |
| EV / EBITDA | 11.75 |
| EV / EBIT | 13.98 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.96.
| Current Ratio | 1.54 |
| Quick Ratio | 0.96 |
| Debt / Equity | 0.96 |
| Debt / EBITDA | 1.71 |
| Debt / FCF | n/a |
| Interest Coverage | 18.03 |
Financial Efficiency
Return on equity (ROE) is 36.88% and return on invested capital (ROIC) is 28.30%.
| Return on Equity (ROE) | 36.88% |
| Return on Assets (ROA) | 12.04% |
| Return on Invested Capital (ROIC) | 28.30% |
| Return on Capital Employed (ROCE) | 22.54% |
| Weighted Average Cost of Capital (WACC) | 5.38% |
| Revenue Per Employee | $866,813 |
| Profits Per Employee | $243,387 |
| Employee Count | 75,000 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.32 |
Taxes
In the past 12 months, Merck & Co. has paid $2.80 billion in taxes.
| Income Tax | 2.80B |
| Effective Tax Rate | 13.31% |
Stock Price Statistics
The stock price has increased by +32.84% in the last 52 weeks. The beta is 0.30, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +32.84% |
| 50-Day Moving Average | 112.58 |
| 200-Day Moving Average | 91.86 |
| Relative Strength Index (RSI) | 61.19 |
| Average Volume (20 Days) | 12,821,117 |
Short Selling Information
The latest short interest is 28.13 million, so 1.14% of the outstanding shares have been sold short.
| Short Interest | 28.13M |
| Short Previous Month | 33.65M |
| Short % of Shares Out | 1.14% |
| Short % of Float | 1.14% |
| Short Ratio (days to cover) | 2.03 |
Income Statement
In the last 12 months, Merck & Co. had revenue of $65.01 billion and earned $18.25 billion in profits. Earnings per share was $7.28.
| Revenue | 65.01B |
| Gross Profit | 50.20B |
| Operating Income | 24.47B |
| Pretax Income | 21.07B |
| Net Income | 18.25B |
| EBITDA | 29.11B |
| EBIT | 24.47B |
| Earnings Per Share (EPS) | $7.28 |
Full Income StatementBalance Sheet
The company has $14.57 billion in cash and $50.53 billion in debt, with a net cash position of -$35.97 billion or -$14.55 per share.
| Cash & Cash Equivalents | 14.57B |
| Total Debt | 50.53B |
| Net Cash | -35.97B |
| Net Cash Per Share | -$14.55 |
| Equity (Book Value) | 52.66B |
| Book Value Per Share | 21.26 |
| Working Capital | 15.19B |
Full Balance SheetCash Flow
| Operating Cash Flow | 16.47B |
| Capital Expenditures | -4.11B |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 77.21%, with operating and profit margins of 37.64% and 28.08%.
| Gross Margin | 77.21% |
| Operating Margin | 37.64% |
| Pretax Margin | 32.41% |
| Profit Margin | 28.08% |
| EBITDA Margin | 44.77% |
| EBIT Margin | 37.64% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of $3.40, which amounts to a dividend yield of 2.79%.
| Dividend Per Share | $3.40 |
| Dividend Yield | 2.79% |
| Dividend Growth (YoY) | 5.06% |
| Years of Dividend Growth | 15 |
| Payout Ratio | 45.60% |
| Buyback Yield | 1.34% |
| Shareholder Yield | 4.08% |
| Earnings Yield | 5.96% |
| FCF Yield | n/a |
Dividend DetailsAnalyst Forecast
The average price target for Merck & Co. is $123.21, which is 1.24% higher than the current price. The consensus rating is "Buy".
| Price Target | $123.21 |
| Price Target Difference | 1.24% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 2.62% |
| EPS Growth Forecast (5Y) | 6.45% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on February 17, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Feb 17, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Merck & Co. has an Altman Z-Score of 3.5 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.5 |
| Piotroski F-Score | 5 |
